NASDAQ : LBRX
LB Pharmaceuticals Inc — Financial statements
Healthcare · Biotechnology · United States
Last price 39.7 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.28B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 24.24M | 13.26M | 13.66M | 3.53M | 1.46M |
| Research & Development | 67.13M | 16.24M | 51.17M | 7.84M | 1.35M |
| Operating Expenses | 91.38M | 29.50M | 64.83M | 11.38M | 2.81M |
| Operating Income | -91.38M | -29.50M | -64.83M | -11.38M | -2.81M |
| Interest Expense | -4.83M | -2.15M | |||
| Interest & Investment Income | 9.33M | 3.92M | 1.72M | 811.00K | 73.00K |
| Other Non Operating Income (Expenses) | 120.00K | 1.16M | -947.00K | 16.22M | -9.46M |
| EBT Excluding Unusual Items | -81.92M | -24.42M | -64.06M | 833.00K | -14.35M |
| Merger & Restructuring Charges | -1.86M | -900.00K | |||
| Gain (Loss) on Sale of Investments | 119.00K | 955.00K | 328.00K | 2.00K | |
| Other Unusual Items | -1.90M | -7.43M | |||
| Pretax Income | -85.68M | -25.20M | -63.10M | -6.27M | -14.35M |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -85.69M | -25.20M | -63.10M | -6.28M | -14.35M |
| Net Income to Common | -85.69M | -25.20M | -63.10M | -6.28M | -14.35M |
| Shares Outstanding (Basic) | 22.46M | 8.05M | 358.23K | 249.61K | 231.08K |
| Shares Outstanding (Diluted) | 22.46M | 8.05M | 358.23K | 249.61K | 231.08K |
| EPS (Basic) | -3.81 | -3.13 | -176.15 | -25.14 | -62.09 |
| EPS (Diluted) | -3.81 | -3.13 | -176.15 | -25.14 | -62.09 |
| Free Cash Flow | -82.83M | -35.26M | -53.82M | -12.12M | -2.73M |
| Free Cash Flow Per Share | -3.69 | -4.38 | -150.24 | -48.55 | -11.80 |
| EBITDA | -91.03M | -29.18M | -64.74M | -11.37M | -2.81M |
| D&A For EBITDA | 345.00K | 321.00K | 91.00K | 4.00K | 2.00K |
| EBIT | -91.38M | -29.50M | -64.83M | -11.38M | -2.81M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 283.11M | 250.17M | 22.98M | 14.98M | 21.40M |
| Short-Term Investments | 44.68M | 45.04M | 5.02M | 28.31M | |
| Cash & Short-Term Investments | 327.79M | 295.21M | 28.00M | 43.29M | 21.40M |
| Prepaid Expenses | 4.74M | 2.46M | 458.00K | 2.34M | 76.00K |
| Other Current Assets | 22.77M | 10.76M | 422.00K | 5.00K | 9.00K |
| Total Current Assets | 355.30M | 308.43M | 28.88M | 45.63M | 21.49M |
| Property, Plant & Equipment | 5.61M | 3.73M | 4.16M | 23.00K | 3.00K |
| Other Long-Term Assets | 782.00K | 770.00K | 498.00K | ||
| Total Assets | 361.69M | 312.93M | 33.53M | 45.66M | 21.49M |
| Accounts Payable | 3.49M | 2.13M | 2.32M | 1.39M | 156.00K |
| Accrued Expenses | 19.23M | 4.58M | 5.30M | 1.22M | 313.00K |
| Current Portion of Leases | 844.00K | 730.00K | 487.00K | ||
| Total Current Liabilities | 23.56M | 7.44M | 8.11M | 2.61M | 469.00K |
| Long-Term Debt | 24.15M | ||||
| Long-Term Leases | 4.37M | 2.84M | 3.22M | ||
| Other Long-Term Liabilities | 1.41M | 1.34M | 2.50M | 1.56M | 18.49M |
| Total Liabilities | 29.34M | 11.62M | 13.83M | 4.16M | 43.11M |
| Common Stock | 3.00K | 3.00K | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 532.34M | 430.67M | 9.66M | 6.47M | 6.13M |
| Retained Earnings | -200.19M | -129.53M | -104.32M | -41.22M | -34.95M |
| Comprehensive Income & Other | 186.00K | 168.00K | 111.00K | 274.00K | |
| Total Common Equity | 332.35M | 301.31M | -94.55M | -34.47M | -28.81M |
| Shareholders' Equity | 332.35M | 301.31M | 19.70M | 41.49M | -21.62M |
| Total Liabilities & Equity | 361.69M | 312.93M | 33.53M | 45.66M | 21.49M |
| Total Debt | 5.22M | 3.57M | 3.70M | 24.15M | |
| Net Cash (Debt) | 322.57M | 291.64M | 24.30M | 43.29M | -2.74M |
| Net Cash Per Share | 14.36 | 36.25 | 67.82 | 173.44 | -11.87 |
| Filing Date Shares Outstanding | 32.26M | 28.67M | 251.79K | 249.61K | 231.08K |
| Total Common Shares Outstanding | 28.68M | 25.30M | 251.79K | 249.61K | 231.08K |
| Working Capital | 331.74M | 300.99M | 20.77M | 43.03M | 21.02M |
| Book Value Per Share | 11.59 | 11.91 | -375.53 | -138.11 | -124.68 |
| Tangible Book Value | 332.35M | 301.31M | -94.55M | -34.47M | -28.81M |
| Tangible Book Value Per Share | 11.59 | 11.91 | -375.53 | -138.11 | -124.68 |
| Machinery | 820.00K | 510.00K | 469.00K | 34.00K | 10.00K |
| Leasehold Improvements | 1.98M | 1.49M | 1.49M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -85.69M | -25.20M | -63.10M | -6.28M | -14.35M |
| Depreciation & Amortization | 345.00K | 321.00K | 91.00K | 4.00K | 2.00K |
| Other Amortization | 3.22M | 3.88M | 1.64M | ||
| Asset Writedown & Restructuring Costs | 8.00K | 8.00K | |||
| Loss (Gain) From Sale of Investments | 220.00K | 142.00K | -989.00K | 100.00K | -2.00K |
| Stock-Based Compensation | 10.69M | 4.19M | 3.16M | 295.00K | 431.00K |
| Other Operating Activities | 115.00K | -1.01M | 1.25M | -8.79M | 9.46M |
| Change in Accounts Payable | 19.54M | -910.00K | 5.02M | 1.10M | 131.00K |
| Change in Other Net Operating Assets | -27.63M | -12.74M | -1.70M | -2.41M | -45.00K |
| Operating Cash Flow | -82.39M | -35.21M | -53.05M | -12.09M | -2.73M |
| Capital Expenditures | -435.00K | -52.00K | -769.00K | -25.00K | |
| Investment in Securities | -44.38M | -39.84M | 24.00M | -27.98M | 123.00K |
| Investing Cash Flow | -44.82M | -39.89M | 23.23M | -28.01M | 123.00K |
| Long-Term Debt Issued | 725.00K | 25.00M | |||
| Net Debt Issued (Repaid) | 725.00K | 25.00M | |||
| Issuance of Common Stock | 428.07M | 328.00M | 23.00K | 1.00K | |
| Other Financing Activities | -31.70M | -25.43M | -1.71M | -2.05M | -2.95M |
| Financing Cash Flow | 396.37M | 302.56M | 38.31M | 33.68M | 22.96M |
| Net Cash Flow | 269.16M | 227.47M | 8.50M | -6.42M | 20.36M |
| Free Cash Flow | -82.83M | -35.26M | -53.82M | -12.12M | -2.73M |
| Free Cash Flow Per Share | -3.69 | -4.38 | -150.24 | -48.55 | -11.80 |
| Levered Free Cash Flow | -53.92M | -27.23M | -28.34M | -6.09M | |
| Unlevered Free Cash Flow | -53.92M | -27.23M | -28.34M | -6.96M | |
| Cash Interest Paid | 1.98M | ||||
| Cash Income Tax Paid | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Change in Working Capital | -8.09M | -13.65M | 3.31M | -1.31M | 86.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 1.27B | 563.16M | |||
| Enterprise Value | 945.86M | 252.35M | |||
| Last Close Price | 39.70 | 22.26 | |||
| PB Ratio | 3.43 | 1.87 | |||
| P/TBV Ratio | 3.85 | 1.87 | |||
| Debt / Equity Ratio | 0.02 | 0.01 | 0.19 | -1.12 | |
| Net Debt / Equity Ratio | -0.97 | -0.97 | -1.23 | -1.04 | -0.13 |
| Net Debt / EBITDA Ratio | 3.54 | 9.99 | 0.38 | 3.81 | -0.98 |
| Net Debt / FCF Ratio | 3.89 | 8.27 | 0.45 | 3.57 | -1.01 |
| Quick Ratio | 13.91 | 39.67 | 3.45 | 16.61 | 45.64 |
| Current Ratio | 15.08 | 41.45 | 3.56 | 17.51 | 45.82 |
| Return on Equity (ROE) | -50.00% | -15.70% | -206.22% | -63.14% | |
| Return on Assets (ROA) | -29.98% | -10.64% | -102.33% | -21.18% | |
| Return on Capital Employed (ROCE) | -27.00% | -9.70% | -255.00% | -26.40% | -13.40% |
| Earnings Yield | -9.70% | -4.48% | |||
| FCF Yield | -6.48% | -6.26% | |||
| Buyback Yield / Dilution | -8,821.45% | -2,145.81% | -43.52% | -8.02% |